Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Melanotan-I

Afamelanotide, MT-I, [Nle4-D-Phe7]-α-MSH, Scenesse, CUV-1647

Quick Stats
Studies 225
Trials 100
Score 3
1992 pubmed

Effects of a melanotropic peptide on melanoma cell growth, metastasis, and invasion.

Gehlsen. K R KR; Hadley. M E ME; Levine. N N; Ray. C G CG; Hendrix. M J MJ

Key Findings

  • The peptide did not increase the size of primary melanoma tumors in mice.
  • It did not raise the number of spontaneous lung metastases.
  • Melanoma cells treated with the peptide did not show greater invasion through a basement‑membrane model.

Practical Outcomes

  • For biohackers who use melanotan‑I for tanning, this study suggests the peptide is unlikely to accelerate melanoma growth or spread, at least in the mouse model tested. While reassuring, the data are pre‑clinical, so users should still monitor skin health and avoid use if they have a history of melanoma or suspicious lesions.

Summary

In mice with a type of skin cancer, giving the super‑potent melanin‑stimulating peptide (the same kind used in melanotan‑I) did not make the tumors grow bigger, spread to the lungs, or become more invasive. Survival was the same as in untreated mice.

Abstract

Melanocyte stimulating hormone (alpha-MSH, alpha-melanotropin),Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Ly-Pro-Va l-NH2, regulates melanogenesis within epidermal melanocytes of many animals. An MSH analogue ([Nle4,D-Phe7]alpha-MSH) that exhibits superpotency and prolonged biological activity has been synthesized, biologically characterized, and is presently in clinical trials to determine its possible clinical use in tanning of the skin. It also has potential for the diagnosis, localization, and chemotherapy of melanoma. The effects of this analogue on the growth, metastatic behavior, and invasive potential of a melanotic variant of Cloudman S-91 murine melanoma are reported here. In an intracutaneous murine model of melanoma cell tumor growth, the analogue did not increase primary tumor growth (size) after the period of administration of the peptide hormone analogue and did not affect spontaneous lung metastases. Survival times for the control and melanotropin-treated groups were similar, suggesting that overall tumor burden was not affected by treatment with the hormone analogue. Last, melanoma cell invasion through a human amniotic basement membrane in vitro was not enhanced compared to untreated cells.

Study Information

Provider

pubmed

Year

1992

DOI

10.1111/j.1600-0749.1992.tb00540.x